Quarterly report pursuant to Section 13 or 15(d)

Revenue (Tables)

v3.20.1
Revenue (Tables)
3 Months Ended
Mar. 31, 2020
Revenue  
Summary of revenue categories

Three months ended

Three months ended

 

 

March 31, 

March 31, 

     

2020

    

2019

Development revenue: GSK Collaboration and License Agreement

 

$

761

 

$

 

$

761

 

$

Schedule of movements in deferred revenue

Deferred revenue

Deferred revenue at January 1, 2020

 

$

2,128

Amounts invoiced in the period

 

50,000

Revenue in the period

(761)

Foreign exchange arising on consolidation(1)

(2,735)

Deferred revenue at March 31, 2020

$

48,632